COMT Val158Met Affects the Analgesic Response to Acupuncture Among Cancer Survivors With Chronic Pain
The Journal of Pain · 2023-09 · 24 (9) · 1721-1730
DOI: 10.1016/j.jpain.2023.05.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Pain, 2023-09. Verfasst von Mingxiao Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Chronic Pain, Cancer Survivors, Acupuncture Therapy, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Congressionally Directed Medical Research Programs, National Institutes of Health.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Catechol-O-methyltransferase (COMT) is the major enzyme involved in the catabolism of dopamine, a neurotransmitter in the brain's reward system. The common COMT polymorphism Val158Met (rs4680 G>A) modulates pain response to opioids through a reward-motivated mechanism; however, its role in nonpharmacological pain medicine has not been clinically characterized. We genotyped 325 participants from a randomized controlled trial of cancer survivors with chronic musculoskeletal pain. We found that carrying methionine at position 158 (158Met) of COMT, encoded by the A allele, significantly increased the analgesic response to electroacupuncture (74% vs 50%; odds ratio [OR]: 2.79; 95% confidence interval [CI]: 1.31, 6.05; P < .01), but not to auricular acupuncture (68% vs 60%; OR: 1.43; 95% CI: .65, 3.12; P = .37) or usual care (24% vs 18%; OR: 1.46; 95% CI: .38, 7.24; P = .61) compared to Val/Val. These findings raise the possibility that COMT Val158Met might be an important predictor of analgesic response to electroacupuncture, providing novel insights into precision nonpharmacologic pain management tailored to individual genetic backgrounds. PERSPECTIVE: This work suggests the modulating effects of the polymorphism in COMT Val158Met on the response to acupuncture. Further research needs to validate these findings, increase the mechanistic understanding of acupuncture, and guide further development of acupuncture as a precision pain management strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Bioinformatics Core Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: maoj@mskcc.org.
Förderung
- NCI NIH HHS
- Congressionally Directed Medical Research Programs
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Yang, M., Baser, R. E., Khanin, R., Autuori, I., Li, Q. S., Panageas, K. S., Orlow, I., & Mao, J. J. (2023). COMT Val158Met Affects the Analgesic Response to Acupuncture Among Cancer Survivors With Chronic Pain. The Journal of Pain, 24(9), 1721-1730. https://doi.org/10.1016/j.jpain.2023.05.005
Vancouver
Yang M, Baser RE, Khanin R, Autuori I, Li QS, Panageas KS, et al. COMT Val158Met Affects the Analgesic Response to Acupuncture Among Cancer Survivors With Chronic Pain. The Journal of Pain. 2023;24(9):1721-1730. doi:10.1016/j.jpain.2023.05.005
BibTeX
@article{Yang2023,
author = {Yang, Mingxiao and Baser, Raymond E and Khanin, Raya and Autuori, Isidora and Li, Qing S and Panageas, Katherine S and Orlow, Irene and Mao, Jun J},
title = {COMT Val158Met Affects the Analgesic Response to Acupuncture Among Cancer Survivors With Chronic Pain},
journal = {The Journal of Pain},
year = {2023},
volume = {24},
number = {9},
pages = {1721--1730},
doi = {10.1016/j.jpain.2023.05.005}
}
EUVIMED